8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Measurements for assessing the exposure from 3G femtocells

Bioeffects Seen

Authors not listed · 2011

Share:

Long-term health monitoring of childhood exposures requires systematic tracking over decades, not short-term studies.

Plain English Summary

Summary written for general audiences

This study analyzed antiretroviral drug exposure patterns in HIV-exposed but uninfected children born between 1995-2009, tracking how prenatal medication use evolved over time. Researchers found that exposure to combination HIV drugs during pregnancy increased dramatically from 19% in 1997 to 88% in 2009, with nearly universal exposure to certain drug classes by 2009.

Why This Matters

While this study focuses on HIV medications rather than electromagnetic fields, it demonstrates an important principle relevant to EMF health research: the critical need for long-term monitoring of exposure effects in vulnerable populations. Just as researchers recognized the importance of tracking antiretroviral effects on developing children over decades, we need similar vigilance with EMF exposures that have become ubiquitous during the same time period. The study's timeline coincides precisely with the explosion of wireless technology adoption, yet we lack comparable systematic tracking of EMF exposure patterns and health outcomes in children. The researchers' call for continued follow-up to assess long-term effects of these exposures should serve as a model for EMF health surveillance.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2011). Measurements for assessing the exposure from 3G femtocells.
Show BibTeX
@article{measurements_for_assessing_the_exposure_from_3g_femtocells_ce1146,
  author = {Unknown},
  title = {Measurements for assessing the exposure from 3G femtocells},
  year = {2011},
  doi = {10.1089/apc.2011.0068},
  
}
DOI: 10.1089/apc.2011.0068PubMed: 21992592

Quick Questions About This Study

By 2009, 88% of HIV-exposed children had prenatal exposure to combination antiretroviral therapy (HAART), representing a dramatic increase from just 19% in 1997. Nearly 99% were exposed to at least one class of these medications.
Among children born in 2009, the most common exposures were zidovudine (73%), lamivudine (72%), tenofovir (39%), and emtricitabine (37%). Protease inhibitor exposure reached 86% by 2009, while NNRTI use declined significantly.
Higher maternal HIV RNA viral loads and lower CD4 counts were associated with increased likelihood of receiving combination antiretroviral therapy during pregnancy. Earlier timing of viral load measurements also correlated with treatment initiation.
The study analyzed data from 1,768 HIV-exposed children born between 1995 and 2009, providing a 14-year window into changing prenatal antiretroviral prescribing patterns as treatment guidelines evolved and new medications became available.
Since antiretroviral use during pregnancy continues to evolve and these medications can cross the placenta, researchers stress the need for ongoing monitoring to assess potential long-term developmental and health effects in exposed children.